Why the study?
A significant group of patients with ventricular tachycardia do not benefit from antiarrhythmic drugs or ablation, prompting evaluation of STereotactic Arrhythmia Radioablation (STAR).
Does STereotactic Arrhythmia Radioablation (STAR) safely treat intractable ventricular tachycardia in patients with structural heart disease?
Does STereotactic Arrhythmia Radioablation (STAR) safely treat intractable ventricular tachycardia in patients with structural heart disease?
The SMART-VT trial protocol outlines a prospective, single-arm study to evaluate the safety of 25 Gy single-fraction stereotactic arrhythmia radioablation for refractory ventricular tachycardia.
STAR may offer option for refractory VT; leaves open efficacy, safety, and durability in larger trials.
Patients with vetricular tachycardia are usually treated with antiarrhythmic drugs and ablation if the arrhythmia substrate is available for invasive treatment. Despite high efficiency of this treatment there is a significant group of patients who do not benefit from available treatment methods, either because they cannot be applied or do not allow for durable control of the disease. For that reason a novel treatment method, STereotactic Arrhythmia Radioablation (STAR) has been proposed and its safety and efficiency is extensively studied throughout the world. The method is based on irradiation of the arrhythmia substrate identified with electrophysiological examination with high-precision image-guided radiosurgical methods usually used for ablation of malignant tumors. Here we present the protocol of the first Polish study on STAR in patients with intractable ventricular tachycardia (STARVT, NCT04642963), designed to test the safety of the method. Secondary endpoints include measures of the treatment efficiency.
No takes yet. Share an insight, caveat, or question.
Miszczyk et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: